Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International has completed dosing for all participants in its Phase 1 clinical trial of the DYAI-100 COVID-19 booster vaccine candidate. No serious adverse events have been reported, indicating a favorable safety profile thus far. This trial aims to assess both the safety and antibody response from the vaccine, produced using Dyadic's innovative C1-cell protein production platform. Results are anticipated in Q2 2023, with a comprehensive study report expected in the second half of the year. The study's success could enhance interest and adoption of Dyadic's technology across various sectors, including academic and governmental organizations.

Dyadic International, a biotechnology company listed on NASDAQ under the symbol DYAI, announced participation in key investor and industry events in March 2023. Notable engagements include the 16th European Conference on Fungal Genetics and the 35th Annual Roth Conference. The company’s innovative microbial platforms aim to meet the rising demand for affordable biopharmaceuticals.

Dyadic International, a biotechnology company, announced that CEO Mark Emalfarb will participate in two investor conferences: the BIO CEO & Investor Conference on February 6, 2023, in New York, and the 35th Annual Roth Conference from March 12-14, 2023, in California. Emalfarb is available for one-on-one meetings during these events. Dyadic focuses on innovative microbial platforms for protein bioproduction and biopharmaceuticals, including its lead asset, the DYAI-100 COVID-19 vaccine candidate. The company aims to enhance access to affordable health solutions globally.

Dyadic International has initiated dosing in its Phase 1 clinical trial for the DYAI-100 COVID-19 booster vaccine candidate. This trial, conducted in South Africa, aims to evaluate the vaccine's clinical safety and antibody response in healthy volunteers aged 18-55. Following regulatory approval from SAHPRA in late 2022, the trial will consist of 15 subjects per cohort with a total randomization scheme of 4:1. Dosing is expected to complete within the first quarter of 2023, with results projected later this year. This marks the first human trial utilizing Dyadic’s C1 protein production platform, highlighting potential advancements in COVID-19 vaccine development.

Dyadic International, Inc. (NASDAQ: DYAI) announced a receipt of approximately $1.27 million from the sale of its equity interest in Alphazyme LLC. This investment came as part of a licensing agreement whereby Dyadic granted a non-exclusive license to its technology. The agreement allows Dyadic to receive milestone and royalty payments from Alphazyme's sales of C1 expressed products, plus potential additional payments based on future sales of Alphazyme's existing products. Dyadic is focused on biopharmaceutical innovations for human and animal health, leveraging its C1-cell technology and other platforms.

Dyadic International will participate in the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12, 2023, in San Francisco, CA. CEO Mark Emalfarb will present on January 8, focusing on advancements in Dyadic's C1-cell protein expression platform and its first Phase 1 clinical trial, expected to commence this month. Emalfarb will discuss the efficacy of C1-produced COVID-19 ferritin nanoparticle vaccines, supported by data from respected institutions.

Dyadic International announced the publication of a study demonstrating its vaccine candidate DYAI-100, a recombinant protein RBD booster for COVID-19, has shown promise in animal models. The study, published in VACCINES, supports the upcoming First-In-Human clinical trial aimed at evaluating safety and immune response. The vaccine demonstrated strong immunogenicity and antiviral efficacy without adverse effects. Importantly, the C1-cell production platform offers a cost-effective and scalable manufacturing process, reinforcing Dyadic's commitment to producing affordable biopharmaceuticals.

Dyadic International received regulatory approval from SAHPRA to initiate a Phase 1 clinical trial for its COVID-19 vaccine candidate, DYAI-100. The company presented significant data at the World Vaccine Congress Europe and announced new collaborations in animal health. As of September 30, 2022, cash and investments totaled $14.2 million. Research and development revenues increased to approximately $880,000 for Q3 2022. Net loss for the quarter was about $1.8 million, consistent with the prior year, but the loss per share improved over nine months.

Dyadic International (NASDAQ: DYAI), a biotechnology firm, has announced participation in key industry events in November 2022, aimed at enhancing its microbial platforms for protein production and biopharmaceutical needs. Key conferences include the RAFT® 14 Conference (Nov 6-9) in Orlando, where CEO Mark Emalfarb will present on Nov 8. Additionally, Dyadic will join the BARDA Industry Day (Nov 15-16) virtually and the Jefferies London Healthcare Conference (Nov 16-19). These events focus on connecting with investors and showcasing advancements in biopharmaceutical products.